HBED: A potential alternative to deferoxamine for iron-chelating therapy
HBED: A potential alternative to deferoxamine for iron-chelating therapy
复制标题
DOI：
10.1182/blood.v91.4.1446
复制
发表时间：
1998-02-15
期刊：
影响因子：
20.3
通讯作者：
Brittenham, GM
中科院分区：
文献类型：
--
作者：
Bergeron, RJ;Wiegand, J;Brittenham, GM
为了研究六齿酚氨基羧酸铁螯合剂N，N-双（2-羟基苄基）乙二胺-N，N-二乙酸（HBED）在慢性输注铁超载治疗中的潜在临床应用价值，我们比较了皮下注射HBED和对照螯合剂去铁胺（DFO）对啮齿动物和灵长类动物铁排泄的影响。在非铁负荷，胆管插管的大鼠中。单次SC注射150 mu mol/kg的HBED，导致净铁排泄量比相同剂量的DFO增加三倍以上。单次SC注射150 μ mol/kg的HBED，在铁负荷的无毛猴中产生的净铁排泄量是相同剂量SC DFO后的两倍多。在输注铁超载的患者中，SC注射HBED可能是长期静脉注射DFO的一种急需的替代方法。(C) 1998年由美国血液病学会出版。
To examine the potential clinical usefulness of the hexadentate phenolic aminocarboxylate iron chelator N,N-bis(2-hydroxybenzyl)ethylenediamine-N,N-diacetic acid (HBED) for the chronic treatment of transfusional iron overload, we compared the iron excretion induced by subcutaneous (SC) injection of HBED and deferoxamine (DFO), the reference chelator, in rodents and primates. In the non-iron-overloaded, bile-duct-cannulated rat. a single SC injection of HBED, 150 mu mol/kg, resulted in a net iron excretion that was more than threefold greater than that after the same dose of DFO. In the iron-loaded Cebus apella monkey, a single SC injection of HBED, 150 mu mol/kg, produced a net iron excretion that was more than twice that observed after the same dose of SC DFO. In patients with transfusional iron overload, SC injections of HBED may provide a much needed alternative to the use of prolonged parenteral infusions of DFO. (C) 1998 by The American Society of Hematology.